HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 2,168: | Line 2,168: | ||
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] | |[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] | ||
|Disease | |Disease | ||
| | |Fei Yang, MD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|SK | |SK | ||
| Line 2,184: | Line 2,184: | ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
|Disease | |Disease | ||
|Parastou Tizro (trainee) | |Parastou Tizro, MD (trainee); | ||
Sumire Kitahara, MD | |||
|3/17/2024 | |3/17/2024 | ||
| | | | ||
| Line 2,221: | Line 2,222: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| | ||
| || || || ||SK|| || | | || || || ||SK|| || | ||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
| Line 2,256: | Line 2,257: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease|| || || | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee), | ||
Andrew Siref, MD | |||
|4/12/2024 | |||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,297: | Line 2,303: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease|| | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD | ||
| || || || ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,304: | Line 2,311: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease|| || || | | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee), | ||
Andrew Siref, MD | |||
|4/12/2024|| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,398: | Line 2,409: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease|| | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | ||
| | |4/1/2024 | ||
| ||Pending|| ||SK|| || | |||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||